RxDoctor Payments Data

Kristie Callahan

Family · Jackson, MSNPI 1093129231

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 681 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 7.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,797in general payments, 2019–2025

Across 681 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$936
  • Novartis$827
  • Acadia Pharmaceuticals Inc$727
  • SK Life Science, Inc.$723
  • Pfizer$660
  • UCB, Inc.$561
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$11,71999%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie64$936
Novartis58$827
Acadia Pharmaceuticals Inc46$727
SK Life Science, Inc.35$723
Pfizer42$660
UCB, Inc.31$561
Teva Pharmaceuticals USA, Inc.27$477
Sanofi21$402
Amgen(2 entities)23$393
Argenx US, Inc.18$392
Genentech USA, Inc.27$389
AstraZeneca(2 entities)21$388
Biogen20$379
Lilly USA, LLC24$350
Amylyx Pharmaceuticals, Inc.17$347
Otsuka America Pharmaceutical, Inc.13$308
ANI Pharmaceuticals, Inc.18$307
Catalyst Pharmaceuticals, Inc.9$235
Jazz Pharmaceuticals Inc.11$230
Medtronic15$215
Bristol Myers Squibb14$210
Lundbeck LLC10$202
Biohaven Pharmaceutical Holding Company Ltd.13$198
Avanir Pharmaceuticals, Inc.11$176
Mallinckrodt Hospital Products Inc.5$169
Neurocrine Biosciences, Inc.9$147
Boston Scientific2$142
Impel Pharmaceuticals Inc.6$126
Biohaven Pharmaceuticals, Inc.8$124
Sunovion Pharmaceuticals Inc.6$98
E.r. Squibb & Sons, L.L.C.7$97
Eisai Inc.5$88
Kyowa Kirin, Inc.4$80
Acorda Therapeutics, Inc3$63
Takeda Pharmaceuticals U.S.A., Inc.3$53
Corium, LLC3$50
Alnylam Pharmaceuticals Inc.3$48
Merz Pharmaceuticals, LLC2$47
EMD Serono, Inc.3$44
Tanabe Pharma America, Inc.3$39
Axsome Therapeutics, Inc.2$37
Amneal Pharmaceuticals LLC2$32
Johnson & Johnson2$27
Novocure Inc.1$25
Sumitomo Pharma America, Inc.2$24
MDD US Operations, LLC1$22
TG Therapeutics, Inc.1$22
Grifols USA, LLC1$22
Merck1$20
Vanda Pharmaceuticals Inc.1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$16
Mylan Specialty L.p.1$16
Cala Health, Inc.1$16
Idorsia Pharmaceuticals US Inc1$15
Kedrion Biopharma, Inc.1$14
Livanova USA, Inc.1$12
Supernus Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,797 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$110,357
Medicare patients
827
Services billed
2,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$72,382
UbrelvyUbrogepant24$32,915
NuedextaDextromethorphan Hbr/Quinidine14$20,309
VimpatLacosamide17$15,707
Aimovig AutoinjectorErenumab-Aooe12$13,747
Ajovy AutoinjectorFremanezumab-Vfrm17$13,048
Emgality PenGalcanezumab-Gnlm19$12,609
MyrbetriqMirabegron12$5,420
Lacosamide22$4,802
Levetiracetam180$4,510
Gabapentin341$4,272
Primidone186$4,062
Carbamazepine78$3,978
Divalproex Sodium53$3,969
Carbidopa-LevodopaCarbidopa/Levodopa221$3,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$660$72,38296 claims
AbbVieUbrelvy$936$32,91524 claims
Avanir Pharmaceuticals, Inc.Nuedexta$176$20,30914 claims
UCB, Inc.Vimpat$561$15,70717 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$32$1,30819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →